Last week, while tweaking a finicky assay late at night, I caught myself overthinking the evolutionary angle behind choosing polyclonal versus monoclonal anti-IgM secondaries, especially when the antigen barely shows up. In practice, how do you weigh robustness against specificity in those low-signal moments, beyond what textbooks suggest?
4 Views
Honestly, my take comes from a few frustrating months chasing weak IgM signals that only appeared on good days. I’ve bounced between reagents depending on how noisy the background felt, and sometimes the “theoretical best” choice didn’t survive real lab life. I remember reading up on basics like the lgm full form, mostly to reset my thinking. In the end, I treat it less like a rule and more like a compromise shaped by the sample, the day, and how patient I’m feeling. That’s just my experience though, not a hard stance.